Home » CELL GENESYS REPORTS HIGHER SURVIVAL WITH GVAX
CELL GENESYS REPORTS HIGHER SURVIVAL WITH GVAX
Cell Genesys has reported that it expects a higher percentage of advanced prostate cancer patients taking cancer vaccine GVAX to survive longer in its second mid-stage clinical trial than in the first.
The company estimates that the median survival in its current 22-patient Phase II trial will be no less than 29.1 months. The median survival is the point in a clinical trial when half the patients have died. The first Phase II trial, which followed 34 patients, had a median survival of 26.2 months.
The trials followed men with advanced prostate cancer that had spread to other parts of the body and had stopped responding to hormone therapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May